Victoria Johnson

Reporting on cell and gene therapies for @CGT_Live 🧬| @Rutgersnb Class of 2020 🎓 [email protected] 📧 | Tweets my own ✍️ 🇵🇭

Articles

Zimislecel Enables Insulin Independence in 10 Participants with Type 1 Diabetes

1 week ago | hcplive.com | Victoria Johnson

Ten of 12 participants with type 1 diabetes (T1D) that received a full dose of zimislecel, Vertex Pharmaceutical’s islet cell therapy formerly known as VX-880, in phase 2 of the FORWARD study remain insulin-independent after 1 year of follow-up.1 These findings were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions, held June 20-23, in Chicago, Illinois, by investigator Michael Rickels, MD, MS, Willard and Rhoda Ware professor in diabetes and metabolic diseases,...
ADA Symposium Focuses on New Guidelines for SOC of Overweight and Obesity

1 week ago | hcplive.com | Victoria Johnson

Around 110 million American adults are impacted by obesity and up to 53% of new cases of type 2 diabetes (T2D) are attributable to obesity. New research continues to evolve care and guidelines for managing obesity.
Rheumatoid Arthritis Burden Has Surged Over Last 30 Years

1 week ago | hcplive.com | Victoria Johnson

The global rheumatoid arthritis (RA) burden has significantly increased worldwide, according to a large AI-powered study that also revealed local hotspots and a growing trend of RA in younger people.1 “While previous Global Burden of Disease (GBD) studies have provided important insights, they have largely focused on high-level descriptions and visualizations at global and national scales, failing to capture local disparities or the dynamic interactions between socioeconomic development and...
ADA 2025 Late-Breaking Trials Preview

1 week ago | hcplive.com | Victoria Johnson

The 2025 American Diabetes Association (ADA) Scientific Sessions aim to capture the accelerating pace of innovation in diabetes and obesity care. Following a year marked by major clinical milestones, this year’s meeting, taking place June 20–24 in Chicago, brings forward a wave of late-breaking data and pivotal phase 2 and 3 trial results that could reshape treatment standards across the metabolic disease spectrum.
New Data Supports TNX-102 SL Efficacy Ahead of PDUFA

1 week ago | hcplive.com | Victoria Johnson

New findings from trials of TNX-102 SL support its efficacy in targeting nonrestorative sleep and improving pain in people with fibromyalgia.1 TNX-102 SL is a sublingual formulation of cyclobenzaprine with a PDUFA goal date of August 15, 2025, to become the potential first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in over 15 years.2 These findings, from a phase 1 pharmacokinetic (PK) study and the phase 3 RESILIENT...
New Research Highlights Potential Marker for Chronic Pain in Fibromyalgia

1 week ago | hcplive.com | Victoria Johnson

Mu-Lympho-Marker (MLM) has demonstrated promise as a marker for chronic pain (CP) in people with fibromyalgia (FM), according to new findings from an observational study.1“The absence of a dependable diagnostic test represents a significant obstacle in advancing the comprehension of CP and in this specific contest of FM pain condition. Adding to the complexity, the lack of specific biomarkers for CP further hampers the FM treatment and often causes tensions between patients and physicians.
Biologics and Beyond: Clinical Perspectives on Managing Complex Airway Inflammation

2 weeks ago | hcplive.com | Victoria Johnson

Over the last decade, the landscape of respiratory care has undergone a dramatic transformation, driven by advances in the understanding of asthma and chronic obstructive pulmonary disease (COPD) pathophysiology and the emergence of targeted biologic therapies. Where treatment once centered largely on inhaled corticosteroids and bronchodilators, the field has entered a new era defined by phenotypic precision, biomarker-driven strategies, and earlier, more tailored intervention.
Inebilizumab Efficacy and Safety Consistent Across Demographic Subgroups of IgG4-RD

2 weeks ago | hcplive.com | Victoria Johnson

A new post-hoc analysis of the MITIGATE trial, a pivotal trial for the approval of inebilizumab for people with IgG4-related disease (IgG4-RD), supports the use of the therapy across various demographic subgroups of the disease.1These findings were presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 in Barcelona, Spain, taking place June 11-14, 2025.
New Data Further Support Safety of Upadacitinib With 26-Week GC Taper for Giant Cell Arteritis

2 weeks ago | hcplive.com | Victoria Johnson

New research examining the rates of serious infections in people with giant cell arteritis (GCA) supports the use of upadacitinib 15 mg with a shorter glucocorticoid (GC) tapering than placebo with a longer taper.1These findings were presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 in Barcelona, Spain, taking place June 11-14, 2025.
Higher Dose Pegloticase Q4W Feasible for Uncontrolled Gout

2 weeks ago | hcplive.com | Victoria Johnson

New research suggests that monthly (Q4W), higher doses of pegloticase are feasible for people with uncontrolled gout while maintaining safety and efficacy comparable to that of pegloticase 8 mg Q2W in the MIRROR randomized control trial (RCT).1The MIRROR RCT previously evaluated pegloticase Q2W dosing with MTX coadminstration.